In this report, the study analysis was given on a worldwide scale, for instance, present and traditional Gastrointestinal Stromal Tumor (GIST) Druggrowth analysis, competitive analysis, and also the growth prospects of the central regions. The report gives an exhaustive investigation of this market at country & regional levels, and provides an analysis of the industry trends in each of the sub-segments, from sales, revenue and consumption. A quantitative and qualitative analysis of the main players in related regions is introduced, from the perspective of sales, revenue and price.
According to XYZResearch, the global Gastrointestinal Stromal Tumor (GIST) Drug market was valued at USD xxx million in 2019, and it is expected to reach a value of USD xxx million by 2026, at a CAGR of xx% over the forecast period 2021-2026. Correspondingly, the forecast analysis of Gastrointestinal Stromal Tumor (GIST) Drug industry comprises of Asia, North America, South America, Middle East and Africa, Europe, with the sales and revenue data in each of the sub-segments.
At the upcoming section, this report discusses industrial policy, economic environment, in addition to the fabrication processes and cost structures of the industry. And this report encompasses the fundamental dynamics of the market which include drivers, opportunities, and challenges faced by the industry. Additionally, this report showed a keen market study of the main consumers, raw material manufacturers and distributors, etc.
Geographically, this report is segmented into several key Regions, with production, consumption, revenue (M USD), market share and growth rate of Gastrointestinal Stromal Tumor (GIST) Drug in these regions, from 2014 to 2026 (forecast), covering
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
South America (Brazil, Argentina, Columbia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Global Gastrointestinal Stromal Tumor (GIST) Drug market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including
Ariad Pharmaceuticals, Inc.
Arog Pharmaceuticals, Inc.
Array BioPharma Inc.
Astex Pharmaceuticals, Inc.
Blueprint Medicines Corporation
Boston Biomedical, Inc.
Calithera Biosciences, Inc.
Chipscreen Biosciences Ltd
Deciphera Pharmaceuticals, LLC
F. Hoffmann-La Roche Ltd.
Horizon Pharma Plc
Immunicum AB
Jiangsu Hengrui Medicine Co., Ltd.
Kolltan Pharmaceuticals, Inc.
Natco Pharma Limited
Nerviano Medical Sciences S.r.l.
Novartis AG
Omeros Corporation
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
Amcasertib
Anagrelide hydrochloride CR
APG-1351
Binimetinib
Others
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate of Gastrointestinal Stromal Tumor (GIST) Drug for each application, including
Clinic
Hospital
Others
If you have any special requirements, please let us know and we will offer you the report as you want.
Table of Contents
Global Gastrointestinal Stromal Tumor (GIST) Drug Market by Manufacturers, Regions, Type and Application, Forecast to 2026
1 Report Overview
1.1 Definition and Specification
1.2 Report Overview
1.2.1 Manufacturers Overview
1.2.2 Regions Overview
1.2.3 Type Overview
1.2.4 Application Overview
1.3 Industrial Chain
1.3.1 Gastrointestinal Stromal Tumor (GIST) Drug Overall Industrial Chain
1.3.2 Upstream
1.3.3 Downstream
1.4 Industry Situation
1.4.1 Industrial Policy
1.4.2 Product Preference
1.4.3 Economic/Political Environment
1.5 SWOT Analysis
2 Market Assessment by Type
2.1 Amcasertib Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
2.2 Anagrelide hydrochloride CR Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
2.3 APG-1351 Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
2.4 Binimetinib Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
2.5 Others Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
3 Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Market Assessment by Type
3.1 Asia Pacific Market Performance (Sales, Revenue)
3.2 Key Players in Asia Pacific
4 North America Gastrointestinal Stromal Tumor (GIST) Drug Market Assessment by Type
4.1 North America Market Performance (Sales, Revenue)
4.2 Key Players in North America
5 Europe Gastrointestinal Stromal Tumor (GIST) Drug Market Assessment by Type
4.1 Europe Market Performance (Sales, Revenue)
4.2 Key Players in Europe
6 South America Gastrointestinal Stromal Tumor (GIST) Drug Market Assessment by Type
4.1 South America Market Performance (Sales, Revenue)
4.2 Key Players in South America
7 Middle Easr and Africa Gastrointestinal Stromal Tumor (GIST) Drug Market Assessment by Type
4.1 Middle Easr and Africa Market Performance (Sales, Revenue)
4.2 Key Players in Middle Easr and Africa
8 World Gastrointestinal Stromal Tumor (GIST) Drug Market Assessment by Type
8.1 Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Market Assessment by Application (Consumption and Market Share)
8.2 North America Gastrointestinal Stromal Tumor (GIST) Drug Market Assessment by Application (Consumption and Market Share)
8.3 Europe Gastrointestinal Stromal Tumor (GIST) Drug Market Assessment by Application (Consumption and Market Share)
8.4 South America Gastrointestinal Stromal Tumor (GIST) Drug Market Assessment by Application (Consumption and Market Share)
8.5 Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Market Assessment by Application (Consumption and Market Share)
9 Company Profiles/Analysis
9.1 Ariad Pharmaceuticals, Inc.
9.1.1 Ariad Pharmaceuticals, Inc. Profiles
9.1.2 Ariad Pharmaceuticals, Inc. Product Portfolio
9.1.3 Ariad Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Business Performance
9.1.4 Ariad Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Business Development and Market Status
9.2 Arog Pharmaceuticals, Inc.
9.2.1 Arog Pharmaceuticals, Inc. Profiles
9.2.2 Arog Pharmaceuticals, Inc. Product Portfolio
9.2.3 Arog Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Business Performance
9.2.4 Arog Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Business Development and Market Status
9.3 Array BioPharma Inc.
9.3.1 Array BioPharma Inc. Profiles
9.3.2 Array BioPharma Inc. Product Portfolio
9.3.3 Array BioPharma Inc. Gastrointestinal Stromal Tumor (GIST) Drug Business Performance
9.3.4 Array BioPharma Inc. Gastrointestinal Stromal Tumor (GIST) Drug Business Development and Market Status
9.4 Astex Pharmaceuticals, Inc.
9.4.1 Astex Pharmaceuticals, Inc. Profiles
9.4.2 Astex Pharmaceuticals, Inc. Product Portfolio
9.4.3 Astex Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Business Performance
9.4.4 Astex Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Business Development and Market Status
9.5 Blueprint Medicines Corporation
9.5.1 Blueprint Medicines Corporation Profiles
9.5.2 Blueprint Medicines Corporation Product Portfolio
9.5.3 Blueprint Medicines Corporation Gastrointestinal Stromal Tumor (GIST) Drug Business Performance
9.5.4 Blueprint Medicines Corporation Gastrointestinal Stromal Tumor (GIST) Drug Business Development and Market Status
9.6 Boston Biomedical, Inc.
9.6.1 Boston Biomedical, Inc. Profiles
9.6.2 Boston Biomedical, Inc. Product Portfolio
9.6.3 Boston Biomedical, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Business Performance
9.6.4 Boston Biomedical, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Business Development and Market Status
9.7 Calithera Biosciences, Inc.
9.7.1 Calithera Biosciences, Inc. Profiles
9.7.2 Calithera Biosciences, Inc. Product Portfolio
9.7.3 Calithera Biosciences, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Business Performance
9.7.4 Calithera Biosciences, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Business Development and Market Status
9.8 Chipscreen Biosciences Ltd
9.8.1 Chipscreen Biosciences Ltd Profiles
9.8.2 Chipscreen Biosciences Ltd Product Portfolio
9.8.3 Chipscreen Biosciences Ltd Gastrointestinal Stromal Tumor (GIST) Drug Business Performance
9.8.4 Chipscreen Biosciences Ltd Gastrointestinal Stromal Tumor (GIST) Drug Business Development and Market Status
9.9 Deciphera Pharmaceuticals, LLC
9.9.1 Deciphera Pharmaceuticals, LLC Profiles
9.9.2 Deciphera Pharmaceuticals, LLC Product Portfolio
9.9.3 Deciphera Pharmaceuticals, LLC Gastrointestinal Stromal Tumor (GIST) Drug Business Performance
9.9.4 Deciphera Pharmaceuticals, LLC Gastrointestinal Stromal Tumor (GIST) Drug Business Development and Market Status
9.10 F. Hoffmann-La Roche Ltd.
9.10.1 F. Hoffmann-La Roche Ltd. Profiles
9.10.2 F. Hoffmann-La Roche Ltd. Product Portfolio
9.10.3 F. Hoffmann-La Roche Ltd. Gastrointestinal Stromal Tumor (GIST) Drug Business Performance
9.10.4 F. Hoffmann-La Roche Ltd. Gastrointestinal Stromal Tumor (GIST) Drug Business Development and Market Status
9.11 Horizon Pharma Plc
9.12 Immunicum AB
9.13 Jiangsu Hengrui Medicine Co., Ltd.
9.14 Kolltan Pharmaceuticals, Inc.
9.15 Natco Pharma Limited
9.16 Nerviano Medical Sciences S.r.l.
9.17 Novartis AG
9.18 Omeros Corporation
10 World Gastrointestinal Stromal Tumor (GIST) Drug Market Assessment by Players
10.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Sales (K Units) and Market Share by Players 2014-2020
10.2 Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue (M USD) and Market Share by Players 2014-2020
10.3 Global Gastrointestinal Stromal Tumor (GIST) Drug Price (USD/Unit) of Players 2014-2020
10.4 Global Gastrointestinal Stromal Tumor (GIST) Drug Gross Margin of Players 2014-2020
10.5 Market Concentration
11 Regional Market Performance by Segment of Players
11.1 North America
11.1.1 North America Gastrointestinal Stromal Tumor (GIST) Drug Sales Assessment of Players 2014-2020
11.1.2 North America Gastrointestinal Stromal Tumor (GIST) Drug Revenue Assessment of Players 2014-2020
11.1.3 North America Gastrointestinal Stromal Tumor (GIST) Drug Price Assessment of Players 2014-2020
11.1.4 North America Gastrointestinal Stromal Tumor (GIST) Drug Gross Margin Assessment of Players 2014-2020
11.1.5 Market Concentration
11.2 Europe
11.2.1 Europe Gastrointestinal Stromal Tumor (GIST) Drug Sales Assessment of Players 2014-2020
11.2.2 Europe Gastrointestinal Stromal Tumor (GIST) Drug Revenue Assessment of Players of Manufacturers 2014-2020
11.2.3 Europe Gastrointestinal Stromal Tumor (GIST) Drug Price Assessment of Players 2014-2020
11.2.4 Europe Gastrointestinal Stromal Tumor (GIST) Drug Gross Margin Assessment of Players 2014-2020
11.2.5 Market Concentration
11.3 Asia-Pacific Market Performance for Manufacturers
11.3.1 Asia-Pacific Gastrointestinal Stromal Tumor (GIST) Drug Sales Assessment of Players 2014-2020
11.3.2 Asia-Pacific Gastrointestinal Stromal Tumor (GIST) Drug Revenue Assessment of Players 2014-2020
11.3.3 Asia-Pacific Gastrointestinal Stromal Tumor (GIST) Drug Price Assessment of Players 2014-2020
11.3.4 Asia-Pacific Gastrointestinal Stromal Tumor (GIST) Drug Gross Margin Assessment of Players 2014-2020
11.3.5 Market Concentration
11.4 South America Market Performance for Players
11.4.1 South America Gastrointestinal Stromal Tumor (GIST) Drug Sales Assessment of Players 2014-2020
11.4.2 South America Gastrointestinal Stromal Tumor (GIST) Drug Revenue Assessment of Players 2014-2020
11.4.3 South America Gastrointestinal Stromal Tumor (GIST) Drug Price Assessment of Players 2014-2020
11.4.4 South America Gastrointestinal Stromal Tumor (GIST) Drug Gross Margin Assessment of Players 2014-2020
11.4.5 Market Concentration
11.5 Middle East and Africa Market Performance for Players
11.5.1 Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Sales Assessment of Players 2014-2020
11.5.2 Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Revenue Assessment of Players 2014-2020
11.5.3 Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Price Assessment of Players 2014-2020
11.5.4 Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Gross Margin Assessment of Players 2014-2020
11.5.5 Market Concentration
12 Regional Market Performance by Segment of Countries
12.1 Asia Pacific
12.1.1 Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Sales by Countries/Regions 2014-2020
12.1.2 Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Countries/Regions 2014-2020
12.1.3 Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Average Price by Countries/Regions 2014-2020
12.2 North America
12.2.1 North America Gastrointestinal Stromal Tumor (GIST) Drug Sales by Countries/Regions 2014-2020
12.2.2 North America Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Countries/Regions 2014-2020
12.2.3 North America Gastrointestinal Stromal Tumor (GIST) Drug Average Price by Countries/Regions 2014-2020
12.3 Europe
12.3.1 Europe Gastrointestinal Stromal Tumor (GIST) Drug Sales by Countries/Regions 2014-2020
12.3.2 Europe Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Countries/Regions 2014-2020
12.3.3 Europe Gastrointestinal Stromal Tumor (GIST) Drug Average Price by Countries/Regions 2014-2020
12.4 South America
12.4.1 South America Gastrointestinal Stromal Tumor (GIST) Drug Sales by Countries/Regions 2014-2020
12.4.2 South America Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Countries/Regions 2014-2020
12.4.3 South America Gastrointestinal Stromal Tumor (GIST) Drug Average Price by Countries/Regions 2014-2020
12.5 Middle East and Africa
12.5.1 Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Sales by Countries/Regions 2014-2020
12.5.2 Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Countries/Regions 2014-2020
12.5.3 Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Average Price by Countries/Regions 2014-2020
13 Technology and Opportunity
13.1 Technology
13.2 Market Opportunity
14 World Gastrointestinal Stromal Tumor (GIST) Drug Sales & Revenue Forecast 2021-2026
14.1 World Gastrointestinal Stromal Tumor (GIST) Drug Sales and Revenue Forecast by Regions 2021-2026
14.1.1 World Gastrointestinal Stromal Tumor (GIST) DrugSales and Market Share by Regions
14.1.2 World Gastrointestinal Stromal Tumor (GIST) DrugRevenue and Market Share by Regions
15 Asia Gastrointestinal Stromal Tumor (GIST) Drug Market Forecast 2021-2026
15.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
15.1.1 Amcasertib
15.1.2 Anagrelide hydrochloride CR
15.1.3 APG-1351
15.1.4 Binimetinib
15.1.5 Others
15.2 Consumption Forecast by Application, 2021-2026
16 North America Gastrointestinal Stromal Tumor (GIST) Drug Market Forecast 2021-2026
16.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
16.1.1 Amcasertib
16.1.2 Anagrelide hydrochloride CR
16.1.3 APG-1351
16.1.4 Binimetinib
16.1.5 Others
16.2 Consumption Forecast by Application, 2021-2026
17 Europe Gastrointestinal Stromal Tumor (GIST) Drug Market Forecast 2021-2026
17.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
17.1.1 Amcasertib
17.1.2 Anagrelide hydrochloride CR
17.1.3 APG-1351
17.1.4 Binimetinib
17.1.5 Others
17.2 Consumption Forecast by Application, 2021-2026
18 South America Gastrointestinal Stromal Tumor (GIST) Drug Market Forecast 2021-2026
18.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
18.1.1 Amcasertib
18.1.2 Anagrelide hydrochloride CR
18.1.3 APG-1351
18.1.4 Binimetinib
18.1.5 Others
18.2 Consumption Forecast by Application, 2021-2026
19 Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Market Forecast 2021-2026
19.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
19.1.1 Amcasertib
19.1.2 Anagrelide hydrochloride CR
19.1.3 APG-1351
19.1.4 Binimetinib
19.1.5 Others
19.2 Consumption Forecast by Application, 2021-2026
20 Price (USD/Unit) and Gross Profit Forecast
20.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Price (USD/Unit) Trend 2021-2026
20.2 Global Gastrointestinal Stromal Tumor (GIST) Drug Gross Profit Trend 2021-2026
21 Conclusion